Bavarian Nordic A/S, a leading biotechnology company headquartered in Denmark (DK), is renowned for its innovative approach in the field of immunotherapy and vaccine development. Founded in 1994, the company has made significant strides in combating infectious diseases and cancer, with a strong operational presence across Europe and North America. Specialising in the development of live virus vaccines and immunotherapies, Bavarian Nordic's core products include the smallpox vaccine, IMVAMUNE®, and the cancer immunotherapy candidate, BN-Brachyury. These offerings are distinguished by their unique mechanisms and robust safety profiles, positioning the company as a key player in the biopharmaceutical industry. With a commitment to advancing public health, Bavarian Nordic has achieved notable milestones, including partnerships with global health organisations, solidifying its reputation as a trusted innovator in vaccine technology.
How does Bavarian Nordic's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bavarian Nordic's score of 44 is higher than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Bavarian Nordic reported total carbon emissions of approximately 10,682,000 kg CO2e, comprising 4,364,000 kg CO2e from Scope 1 and 6,318,000 kg CO2e from Scope 2 emissions. This marked a significant increase from 2022, where total emissions were about 2,753,000 kg CO2e. The company has committed to achieving Net Zero emissions by 2050, in alignment with the Paris Agreement, and is currently focused on defining its carbon footprint reduction pathway through 2024. Bavarian Nordic's emissions data is self-reported and does not include Scope 3 emissions. The company has set near-term targets to reduce its carbon footprint, with a commitment to define its reduction pathway in 2024. The company operates within the pharmaceuticals, biotechnology, and life sciences sector and is headquartered in Denmark (DK). Overall, Bavarian Nordic is taking steps towards sustainability, with a clear commitment to reducing its carbon emissions in the coming years.
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 992,000 | 000,000 | 000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 
| Scope 2 | 1,686,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 000,000 | 0,000,000 | 
| Scope 3 | - | - | - | - | - | - | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bavarian Nordic has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.

Common questions about Bavarian Nordic's sustainability data and climate commitments